David Lamond
CIK 1770790 · last filed 2026-01-21
David Lamond is a corporate insider who has filed 28 SEC Form 4 insider transactions across 4 companies since 2019. The most recent filing, for QNCX, was dated Jan 21, 2026. Across all open-market trades the lifetime net is +$9.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $4.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.32M
4
28
$9.92M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QNCX | Director | 4,627,209 | $0.93 | $4.32M | $601.5K | 10 | 2026-01-21 |
| Quince Therapeutics, Inc. (CRTX) Delisted | Director | 2,036,551 | $1.95 | $3.97M | $8.05M | 11 | 2022-06-09 |
| Lucira Health, Inc. (LHDX) Delisted | Director | 178,910 | $0.45 | $80.9K | $0 | 2 | 2022-06-03 |
| Applied Molecular Transport Inc. (AMTI) Delisted | Director | 1,044,019 | $0.26 | $274.6K | $1.26M | 5 | 2022-05-26 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-21 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2025-01-08 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2023-12-14 | QNCX | Buy (P) | +67,881 | $69.2K | EDGAR |
| 2023-12-07 | QNCX | Buy (P) | +57,369 | $58.1K | EDGAR |
| 2023-12-01 | QNCX | Buy (P) | +43,134 | $40.5K | EDGAR |
| 2023-08-31 | QNCX | Buy (P) | +82,052 | $107.9K | EDGAR |
| 2023-08-17 | QNCX | Buy (P) | +250,000 | $325.7K | EDGAR |
| 2023-05-26 | QNCX | Grant (A) | — | $0 | EDGAR |